James Crowe Jr.

January 11, 2018

VUMC joins national effort to block global pandemics of potentially lethal viruses

The U.S. Defense Advanced Research Projects Agency (DARPA) has signed a five-year cooperative agreement worth up to $28 million with Vanderbilt University Medical Center (VUMC) to develop methods for preventing the global spread of viruses like chikungunya and Zika.

By Bill Snyder
December 14, 2017

Crowe elected a fellow of the National Academy of Inventors

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center (VUMC), has been named a fellow of the National Academy of Inventors (NAI).

By Bill Snyder
October 26, 2017

Vanderbilt leads international effort to develop universal flu vaccine

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.

By Bill Snyder
April 11, 2017

The Human Vaccines Project, Vanderbilt and Illumina join forces to decode the human immunome

The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.

By Bill Snyder
February 23, 2017

Crowe’s pediatric immune response research lauded

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

By Bill Snyder
February 9, 2017

Team isolates new antibodies that may aid RSV vaccine design

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

By Bill Snyder
November 7, 2016

Early study finds antibody that ‘neutralizes’ Zika virus

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
By Bill Snyder
September 8, 2016

Investigators create ‘Trojan Horse’ to fight Ebola

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.
By Bill Snyder
August 11, 2016

Research team takes aim at Ebola virus ‘decoy protein’

Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.
By Bill Snyder
June 21, 2016

Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system

Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.
By Bill Snyder
April 7, 2016

Potent HIV antibodies suggest new vaccine development approach

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
By Bill Snyder
March 7, 2016

Vanderbilt researchers identify potential antibody treatment for H7 avian flu

Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.
By Bill Snyder
January 21, 2016

Antibodies may be ‘silver bullet’ for Ebola viruses

There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.
By Bill Snyder
1 … 4 5 6 7 8 9